Page 1228 - Basic _ Clinical Pharmacology ( PDFDrive )

1214 Index

Glucocorticoids, 1001. See also Glycerin suppository, 1098 Gonadotropin-releasing hormone (GnRH)
Corticosteroids Glycine antagonists, 678–679
binding of, 27, 27f in brain, 373 Gonadotropins, 673–676
on bone homeostasis, 779 in CNS, 376t, 378 chemistry and pharmacokinetics of,
gout treated with, 663 spasmolytic actions of, 487 673–674
hypercalcemia treated with, 783 Glycopeptide antibiotics, 807–810, 812t clinical pharmacology of, 674–675, 675f
immunosuppressive uses of, 985t, dalbavancin, 809–810, 812t pharmacodynamics of, 674
985–986 teicoplanin, 809, 812t preparations available, 685t
inflammation treated with, 643 telavancin, 809, 812t toxicity and contraindications to, 676
inflammatory bowel disease treated with, vancomycin, 807–809, 812t Good Manufacturing Practice (GMP),
1109 Glycoprotein concentration, alpha 1 -acid, 53 1132
rheumatoid arthritis treated with, Glycopyrrolate, 126f, 135t. See also Musca- Goserelin, 676, 972
658–659 rinic receptor blockers Gossypol, 745
Glucocorticoids, naturally occurring, Glycosides, cardiac, 217. See also Digitalis; Gout
704–709 Digoxin description of, 265, 659–660, 660f
pharmacodynamics of drug interactions of, 1165t drugs for, 659–663
anti-inflammatory and immunosup- heart failure treated with, 213, 217–220, allopurinol, 661–662, 662f
pressive, 708 219f, 225t colchicine, 660f, 660–661
catabolic and antianabolic, 708 Glyphosate, 1013f, 1014 febuxostat, 662–663
mechanism of action in, 705–707, GnRH receptor antagonists, 678–679 glucocorticoids, 663
707f Goiter interleukin-1 inhibitors, 663
metabolic, 707–708 nontoxic, 699 NSAIDs, 661
physiologic, 707 toxic multinodular, 699 pegloticase, 663
pharmacokinetics of, 704–705, 705f toxic uninodular, 699 preparations available, 664t
biosynthetic pathways in, 704f Golimumab uricosuric agents, 660f, 661
circadian secretion in, 705f description of, 993 G6PD, 77t, 82. See Glucose 6-phosphate
preparations available, 718t inflammatory bowel disease treated with, dehydrogenase (G6PD)
structures of, 706f 1110–1112, 1111t GP IIb/IIIa antagonists, 621
Glucosamine, 1142–1143 rheumatic disorders treated with, 654f, G protein-coupled receptor (GPCR), 30,
Glucose 655 30f–31f, 31t
acute alcohol intoxication managed with, Gompertzian model, 951 in addiction, 576, 577f, 577t
403 Gonadal hormones and inhibitors, adrenoceptors as, 138, 138f
blood, self-monitoring of, 753 720–746 phosphorylation in regulation of, 32, 33f
Glucose absorption agents, 761 ovarian, 720–732, 745t G protein-coupled receptor kinases
Glucose 6-phosphate dehydrogenase for contraception in women, 732–737 (GRKs), 32, 33f, 141
(G6PD) preparations available, 745t G proteins, 30, 30f, 31f, 31t
characteristics of, 77t testicular, 740–745 Graded dose-response relations, 36, 36f
deficiency of, 82, 82t androgens and anabolic steroids, Gramicidin, 1070
pharmacogenomics of, 82, 82t 740–743, 741t, 745t Grand mal seizures, 413–421. See
Glucose transporters, 749, 750t androgen suppression, 743, 744f, Generalized tonic-clonic
Glulisine, 769t. See also Insulin 745t seizures; Seizures
Glutamate antiandrogens, 743–745, 745t Granisetron
in brain, 373 male contraception, 745 antiemetic properties of, 1104
in CNS, 375, 376t, 377f preparations, 741, 741t, 745t chemical structure of, 1102f
in depression, 534–536 Gonadarche, 721 Granulocyte colony-stimulating factor
Glutamate hypothesis, of schizophrenia, Gonadorelin, 676. See also (G-CSF), 602t, 602–604, 603f,
513 Gonadotropin-releasing hormone (GnRH), 606t, 997t
Glutamate receptor agonists, metabotropic, 669, 669t, 676–678, 739 Granulocyte macrophage colony-
516 actions of, 676 stimulating factor (GM-CSF),
Glutamatergic antipsychotics, 515–516 chemistry and pharmacokinetics of, 676 602t, 602–604, 603f, 606t,
Glutamatergic synapse, excitatory, 412f clinical pharmacology of, 677–678 997t, 998
Glutaraldehyde, 900 in ovarian function, 720 Graves’ disease, 698. See also
Glutathione transferases (GSTs) pharmacodynamics of, 676–677 Hyperthyroidism
description of, 63, 64f, 64t toxicity of, 678 neonatal, 700
genetic polymorphisms in, 67t, 69 uses of, 676 Gray baby syndrome, 823
Glutethimide, 383f Gonadotropin-releasing hormone (GnRH) Grazoprevir, 890
Glyburide, 758, 769t. See also Sulfonylureas agonists, 676–678 Griseofulvin, 860
Glycemic control, for diabetes mellitus, Gonadotropin-releasing hormone (GnRH) dermatologic, 1074
765, 765b. See also Insulin analogs, 745 Groups, drug, 10